Cantor Fitzgerald maintains Vertex stock at Overweight, $480 target
Cantor Fitzgerald reiterated its Overweight rating and a $480.00 price target for Vertex Pharmaceuticals Incorporated (NASDAQ ...
What's Happening With VRTX Stock?
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...